Shanghai Labway Clinical Laboratory Co Ltd
Shanghai Labway Clinical Laboratory Co., Ltd. engages in the sale of in-vitro diagnostic products in China. The company distributes in-vitro diagnostic instruments, reagents, and related accessories and consumables. It also provides third-party medical testing, pathological diagnosis services, precision medicine, CRO, and sample bank laboratory services; scientific research technology and testing… Read more
Shanghai Labway Clinical Laboratory Co Ltd - Asset Resilience Ratio
Shanghai Labway Clinical Laboratory Co Ltd (301060) has an Asset Resilience Ratio of 2.10% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2021)
This chart shows how Shanghai Labway Clinical Laboratory Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Labway Clinical Laboratory Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥54.95 Million | 2.1% |
| Total Liquid Assets | CN¥54.95 Million | 2.10% |
Asset Resilience Insights
- Limited Liquidity: Shanghai Labway Clinical Laboratory Co Ltd maintains only 2.10% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Labway Clinical Laboratory Co Ltd Industry Peers by Asset Resilience Ratio
Compare Shanghai Labway Clinical Laboratory Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
|
Bionet
TWO:1784 |
Diagnostics & Research | 38.62% |
|
Cytogen Inc
KQ:217330 |
Diagnostics & Research | 39.93% |
Annual Asset Resilience Ratio for Shanghai Labway Clinical Laboratory Co Ltd (2019–2021)
The table below shows the annual Asset Resilience Ratio data for Shanghai Labway Clinical Laboratory Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 19.99% | CN¥420.93 Million | CN¥2.11 Billion | +11.79pp |
| 2020-12-31 | 8.20% | CN¥120.63 Million | CN¥1.47 Billion | -8.07pp |
| 2019-12-31 | 16.27% | CN¥227.65 Million | CN¥1.40 Billion | -- |